News Features COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention Michael O'Riordan April 24, 2020
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020